Drug details

Qulipta (atogepant tablets)

type of Antimigraine Agents, CGRP Receptor Antagonists

Qulipta (atogepant) is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of episodic migraine in adults.

The drug is often used to treat Migraine .

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• severe dizziness, and
• elevated liver function tests

The following drugs are related to Qulipta, either as a replacement or used together:

• Aimovig (erenumab-aooe injection, for subcutaneous use)
• Ajovy (fremanezumab-vfrm injection)
• Amerge (naratriptan)
• Relpax (eletriptan hydrobromide)
• Imitrex (sumatriptan succinate)
• Imitrex Injection (sumatriptan succinate injection)
• Imitrex Nasal Spray (sumatriptan nasal spray)
• Reyvow (lasmiditan tablets)
• Maxalt (rizatriptan benzoate)
• Nurtec ODT (rimegepant orally disintegrating tablets, for sublingual or oral use)
• Zecuity (sumatriptan iontophoretic transdermal system)
• Zomig (zolmitriptan)
• Zomig Nasal Spray (zolmitriptan nasal spray)